Form 4: Rapport Therapeutics Director Reid Huber Granted 21,850 Stock Options

Rapport Therapeutics, Inc. Director Reid M. Huber was granted 21,850 stock options with an exercise price of $10.95, vesting upon the earlier of June 17, 2026, or the next Annual Meeting of Stockholders.

Summary

• Reid M. Huber, a Director of Rapport Therapeutics, Inc. (RAPP), was granted 21,850 stock options.
• The options have an exercise price of $10.95 per share.
• The transaction date for the grant was June 17, 2025.
• The options expire on June 17, 2035.
• The shares underlying these options will vest upon the earlier of June 17, 2026, or the date of the next Annual Meeting of Stockholders, contingent on Mr. Huber's continued service.
• Following this transaction, Mr. Huber directly beneficially owns 21,850 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal for aligning interests and retaining talent, though it's a routine compensation event rather than a major strategic announcement.

Positives

• The grant of stock options to Director Reid M. Huber aligns his interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule, tied to continued service, promotes stability in board leadership.

Negatives

• The exercise price of $10.95 means the options only become valuable if the stock price rises above this level, representing a potential dilution if exercised and new shares are issued.

Risks

• The vesting of the options is subject to the reporting person's continued service, meaning the options could be forfeited if service ceases before the vesting date.

Future Outlook

The stock options granted to Director Reid M. Huber are subject to a future vesting schedule, which will occur upon the earlier of June 17, 2026, or the date of the next Annual Meeting of Stockholders, provided his continued service.

Industry Context

This Form 4 filing details an insider transaction, specifically the grant of stock options to a director. Such grants are a common form of executive and director compensation across various industries, including biotechnology, to align leadership incentives with shareholder value creation. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• This document reports a specific insider transaction (stock option grant) and does not contain financial results or project outcomes that can be directly compared to global benchmarks or specific comparable companies/projects. The grant size and exercise price are specific to Rapport Therapeutics' compensation structure and stock valuation at the time of grant.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholders, potentially leading to increased long-term value if the stock price appreciates above the exercise price. It also represents potential future dilution if options are exercised.

Next Steps

• The shares underlying the options will vest upon the earlier of June 17, 2026, or the date of the next Annual Meeting of Stockholders, subject to continued service.

Key Dates

Recommendation

Keywords

Rapport Therapeutics, RAPP, SEC Form 4, Stock Options, Director Compensation, Reid Huber, Equity Grant, Beneficial Ownership, Insider Transaction